Skip to Main Content

Paper Details

A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials.
Med
2
2023
Cancer, RNA, VIGex, cancer, gene expression, gene signature, patient, patients, solid tumor, tumor, tumor-infiltrating lymphocytes
Author NameAffiliation
Benjamin Haibe-KainsPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Canada Ontario Institute for Cancer Research, Canada Vector Institute for Artificial Intelligence
Benjamin Haibe-KainsPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Canada Ontario Institute for Cancer Research, Canada Vector Institute for Artificial Intelligence
Trevor J PughPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Canada Ontario Institute for Cancer Research
Trevor J PughPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Canada Ontario Institute for Cancer Research
Rodrigo DienstmannVall d'Hebron Institute of Oncology
Philippe L BedardPrincess Margaret Cancer Centre, University of Toronto
  • 1 - 6

Datasets

Release 1.2